Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2003
05/01/2003WO2003035045A2 Hard capsules based on polysaccharide and method for the production thereof
05/01/2003WO2003035044A2 Production of starch-gel-based shaped bodies
05/01/2003WO2003035043A2 Pharmaceutical formulation comprising more than 15% tamoxifen
05/01/2003WO2003035042A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
05/01/2003WO2003035041A1 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
05/01/2003WO2003035040A1 Methods of treatment using a gastric retained gabapentin dosage
05/01/2003WO2003035039A1 Methods of treatment using a gastric retained losartan dosage
05/01/2003WO2003035038A1 Method for production of active ingredient-containing pellets
05/01/2003WO2003035037A1 Solid pharmaceutical formulation for a piperazine urea derivative
05/01/2003WO2003035036A1 Montelukast granule formulation
05/01/2003WO2003035035A1 Novel process
05/01/2003WO2003035034A2 Powder for nasal administration of drugs
05/01/2003WO2003035033A1 Metallothioneine-containing liposomes
05/01/2003WO2003035032A2 New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
05/01/2003WO2003035031A1 Stable composition comprising particles in a frozen aqueous matrix
05/01/2003WO2003035030A1 Kit for the preparation of a pharmaceutical composition
05/01/2003WO2003035029A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/01/2003WO2003035028A1 Modulating charge density to produce improvements in the characteristics of spray-dried proteins
05/01/2003WO2003035027A1 Chewable tablet containing lysine
05/01/2003WO2003035026A2 Polysaccharide-based network and method for the production thereof
05/01/2003WO2003035021A1 Potentiated topical composition
05/01/2003WO2003035002A2 Management of postoperative pain
05/01/2003WO2003035000A2 Method for treating non-neuropathic pain
05/01/2003WO2003034999A2 Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers
05/01/2003WO2003034998A2 Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis
05/01/2003WO2003034991A2 Taste masking spill-resistant formulation
05/01/2003WO2003034988A2 Injectable compositions for the controlled delivery of pharmacologically active compound
05/01/2003WO2003034980A2 A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same
05/01/2003WO2003034979A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
05/01/2003WO2003034975A2 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
05/01/2003WO2003034961A1 Terazosin transdermal device and methods
05/01/2003WO2003034960A1 Implantable fluid delivery apparatuses and implantable electrode
05/01/2003WO2003034902A2 Method and system for non-vascular sensor implantation
05/01/2003WO2003034900A2 Sterile, breathable patch for treating wound pain
05/01/2003WO2003034837A1 Dosage system & dosage vehicle therefor
05/01/2003WO2003034822A2 Powdery active ingredient formulations
05/01/2003WO2003026680A3 Method and topical formulation for treating skin conditions associated with aging
05/01/2003WO2003026637A3 Dosage form for treatment of diabetes mellitus
05/01/2003WO2003026628A3 Composite dosage forms having an inlaid portion
05/01/2003WO2003018018A3 Vinorelbine compositions and methods of use
05/01/2003WO2003017976B1 Synergistic mixed poloxamer systems for the solubilisation of drugs
05/01/2003WO2003009829A3 Antiemetic, anti-motion sustained release drug delivery system
05/01/2003WO2003007913A3 Method for oral drug delivery
05/01/2003WO2003007912A3 Lyophilized formulation comprising olanzapine
05/01/2003WO2003005989A3 Granulates containing liposoluble substances and a process for the preparation thereof
05/01/2003WO2003004008A3 Pharmaceutical composition for prophylaxis and treatment of calcium metabolism disorders comprising clodronate in combination with glyceryl palmitostearate
05/01/2003WO2003002152A3 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
05/01/2003WO2002102413A3 Alkali or alkaline earth metal benzoate particles
05/01/2003WO2002096435A3 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
05/01/2003WO2002094223A3 Formulation containing halofantrine hydrochloride
05/01/2003WO2002094215A3 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
05/01/2003WO2002089835A3 Pharmaceutical dosage form of amorphous nelfinavir mesylate
05/01/2003WO2002074806A3 New interferon beta-like molecules
05/01/2003WO2002067897A3 In-situ gel formation of pectins
05/01/2003WO2002065983B1 Hair covering with conditioner
05/01/2003WO2002063260A3 Skin patch including a temperature sensor
05/01/2003WO2002060458A3 Compositions and method of tissue superoxygenation
05/01/2003WO2002056932A9 Thermal vaporizing device for drug delivery
05/01/2003WO2002043739A3 Dermatological formulations containing clindamycin and a zinc-salt
05/01/2003WO2002040056A3 Carrageenan viscoelastics for ocular surgery
05/01/2003WO2002022851A3 Novel tumor-associated marker
05/01/2003WO2002005834A3 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
05/01/2003US20030083739 For treating vascular in-stent restenosis; drug delivery
05/01/2003US20030083647 Osmotic beneficial agent delivery system
05/01/2003US20030083646 Apparatus and methods for variably controlled substance delivery from implanted prostheses
05/01/2003US20030083645 Microneedle transport device
05/01/2003US20030083641 Impedance sensor
05/01/2003US20030083619 Microneedle transdermal transport device
05/01/2003US20030083618 Transdermal transport device with an electrolytic actuator
05/01/2003US20030083610 Compositions and method of tissue superoxygenation
05/01/2003US20030083504 N- (4-carbamimidoyl-phenyl) -glycine derivatives
05/01/2003US20030083421 Liquid crystal polymer selected from a homo- or copolymers of polybenzothiazoles, polybenzimidazoles or polybenzoxazoles; in-situ polymerization in the presence of the carbon nanotubes; high strength fibers
05/01/2003US20030083389 Bifunctional-modified hydrogels
05/01/2003US20030083382 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
05/01/2003US20030083378 Comprises 4-(6-acetyl-3-(3-((4-acetyl-3-hydroxy-2-propylphenyl)thio)propoxy)-2 -propylphenoxy)butyric acid for its selective leukotriene antagonist activity
05/01/2003US20030083366 Combination chemotherapy
05/01/2003US20030083360 Compaction process for manufacture of sodium phenytoin dosage form
05/01/2003US20030083354 Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
05/01/2003US20030083322 For androgenic alopecia or hirsutism; physiologically tolerated film-forming agent and solvent, a plasticizer and compound such as 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2 -(trifluoromethyl)-benzonitrile
05/01/2003US20030083314 Gel-microemulsion formulations
05/01/2003US20030083313 Means of tumor therapy
05/01/2003US20030083310 Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of a parenterally administrable pharmaceutical composition
05/01/2003US20030083309 A mixture comprising a drug complexed with a water soluble polydextrose and a polymer matrix; time-release agents
05/01/2003US20030083296 Antisense modulation of caspase 8 expression
05/01/2003US20030083295 An oligonucleotides are hybridizable with nucleic acids to inhibit the gene expression of enzyme
05/01/2003US20030083286 Comprises penetration enhancer (fatty acid); drug delivery; increases bioavailability of oligonucleotides
05/01/2003US20030082271 Chewing gum containing controlled release acyclic carboxamides
05/01/2003US20030082249 Compositions containing capsaicin and its derivatives, and their use in treating mucositis
05/01/2003US20030082243 Generation of therapeutic microfoam
05/01/2003US20030082240 Porous sphere of calcium carbonate
05/01/2003US20030082239 Antifungal compositions with improved bioavailability
05/01/2003US20030082236 Micronized freeze-dried particles
05/01/2003US20030082234 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
05/01/2003US20030082232 Adjust particle size; induce immunology response; vaccines
05/01/2003US20030082231 Mixture of cellulose ether and chlorophyll chelate compound
05/01/2003US20030082230 Chronotherapeutic dosage forms and methods of treatment using chronotherapy
05/01/2003US20030082229 Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
05/01/2003US20030082228 Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
05/01/2003US20030082227 Drug delivery; multilayer reservoir
05/01/2003US20030082226 Non-steroidal antiinflammatory drug formulations for topical application to the skin
1 ... 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 ... 2991